CLINICAL TRIALS OVERVIEW
We have a robust collection of clinical trials that are actively recruiting to evaluate our drug candidates.
Clinical trials involve the administration of an investigational new drug to human subjects under the supervision of qualified investigators in accordance with good clinical practice (GCP) requirements. A separate submission to the existing investigational new drug (IND) must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials.
Further, an independent review board (IRB) for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its informed consent form, and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans.
Repare Therapeutics is recruiting patients in the U.S. and other countries for the following active clinical trials. Please follow the links below for more information for each study and site location.
Clinical Trials
| Clinical Trial | Overview |
|---|---|
|
POLAR (RP-3467)
RP-3467 + PARP (olaparib) Combo
Phase 1: Actively Recruiting
|
Overview:
This Phase 1, multi-center, open-label, dose-escalation study is evaluating RP-3467, a potential best-in-class Polθ ATPase inhibitor, alone and in combination with the PARP inhibitor, olaparib, in adults with molecularly selected advanced solid tumors. The primary purpose of the study is to assess the safety and tolerability of RP-3467 alone and in combination with olaparib, determine the maximum tolerated dose (MTD) and to define the preliminary recommended Phase 2 dose (RP2D) of RP-3467 in combination with olaparib. Visit ClinicalTrials.gov (NCT06560632) for more information about this trial. |
|
LIONS (RP-1664)
RP-1664
Phase 1: Actively Recruiting
|
Overview:
This Phase 1, multi-center, open-label, dose-escalation study is evaluating RP-1664, a first-in-class, oral selective PLK4 inhibitor, in adult and adolescent patients with TRIM37-high solid tumors. The primary purpose of the study is to investigate safety, pharmacokinetics (PK), pharmacodynamics (PD) and the preliminary efficacy of RP-1664. Visit ClinicalTrials.gov (NCT06232408) for more information about this trial. |
|
MYTHIC
Lunresertib (RP-6306-01) + Debio 0123 Combo
Phase 1: Actively Recruiting
|
Overview:
This Phase 1, multi-center, open-label, dose-escalation study is evaluating Lunresertib (RP-6306) in combination with Debio 0123, a highly selective brain-penetrant, clinical WEE1 inhibitor, in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations as part of an ongoing 50/50, cost-sharing collaboration with Debiopharm. The primary purpose of this study is to assess the safety and tolerability of Lunresertib (RP-6306) in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity. Visit ClinicalTrials.gov (NCT04855656) for more information about this trial. |